The renal cell cancer database Sweden (RCCBaSe) – a new register-based resource for renal cell carcinoma research

Figures & data

Table 1. Data currently collected in the standardized forms in the National Swedish Kidney Cancer Register (NSKCR).

Form	Data recorded
Diagnostics and primary treatment	Tumour information: imaging, biopsy, symptomatic tumour, bilateral, multifocal, tumour size, morphology, malignancy grade (Fuhrman), TNM stage, CT abdomen, preoperative CT thorax, localisation of metastases Treatment information: type of treatment (surgery, surveillance, oncologic treatment, supportive care), type of surgical treatment (nephrectomy, partial nephrectomy, radiofrequency ablation, cryotherapy or renal transplantectomy), surgical technique (open, laparoscopic, robotic, percutaneous), transabdominal or intraperitoneal approach, intention of treatment Dates of: referral, diagnosis, radiology, first visit to specialist, biopsy, treatment decision, surgery Other: smoking status (reported since 2018), if the patient was discussed in a multidisciplinary conference, if the patient had access to individual nurse, had a written health care plan or was included in a study.
Surgical treatment and complications up to 90 days after surgery	Preoperative data: Eastern Cooperative Oncology Group performance status, American Society of Anestesiologists score, Nephrometry score, length, weight, creatinine (pre- and post operative), Intraoperative data: Type of surgical treatment (nephrectomy, partial nephrectomy, radiofrequency ablation, cryotherapy or renal transplantectomy), surgical technique (open, laparoscopic, robotic, percutaneous), surgical approach (transabdominal or intraperitoneal), duration of surgery (min), bleeding (ml), if converted to open surgery, vascular clamping, renal ischemic time, radical surgery, intraoperative complications according to Uro-Clavien-Dindo. Postoperative data: Readmission, complications according to Uro-Clavien-Dindo
Five-year follow up of M0 patients	Recurrence, localisation of recurrence, type of treatment

Figure 1. Flowchart for the creation of the Renal Cell Cancer Database Sweden (RCCBaSe).

Figure 2. Total number of patients with renal cell carcinoma reported to the National Swedish Kidney Cancer Register (NSKCR) per year between 2005 and 2014.

Table 2. Descriptive statistics at the time of diagnosis for patients included in National Swedish Kidney Cancer Register (NSKCR).

	Male	Female
	(n = 5792)	(n = 3624)
Age
Mean (SD)	65.5 (11.6)	67.8 (11.5)
	N (%)	N (%)
Education level
Low	2058 (35.5)	1441 (39.8)
Intermediate	2418 (41.7)	1420 (39.2)
High	1134 (19.6)	659 (18.2)
Missing	182 (3.1)	104 (2.9)
Marital status
Married	3591 (62.0)	1887 (52.1)
Divorced	851 (14.7)	663 (18.3)
Unmarried	1044 (18.0)	378 (10.4)
Widowed	246 (4.2)	639 (17.6)
Missing	60 (1.0)	57 (1.6)
RCC type
Clear cell	4204 (72.6)	2785 (76.8)
Papillary	794 (13.7)	269 (7.4)
Chromophobe	248 (4.3)	203 (5.6)
Collecting duct	20 (0.3)	17 (0.5)
Not possible to classify	113 (2.0)	65 (1.8)
Other kidney histopathology than above	112 (1.9)	60 (1.7)
Missing	301 (5.2)	225 (6.2)
Fuhrman grade
G1	568 (9.8)	479 (13.2)
G2	2335 (40.3)	1512 (41.7)
G3	1518 (26.2)	781 (21.6)
G4	520 (9.0)	260 (7.2)
GX	458 (7.9)	298 (8.2)
Missing	393 (6.8)	294 (8.1)
T stage
T0	1 (0.0)	2 (0.1)
T1a	1719 (29.7)	1111 (30.7)
T1b	1305 (22.5)	870 (24.0)
T2	702 (12.1)	458 (12.6)
T2a	168 (2.9)	107 (3.0)
T2b	116 (2.0)	68 (1.9)
T3a	886 (15.3)	485 (13.4)
T3b	513 (8.9)	299 (8.3)
T3c	29 (0.5)	19 (0.5)
T4	197 (3.4)	114 (3.1)
TX	149 (2.6)	85 (2.3)
Missing	7 (0.1)	6 (0.2)
N stage
N0	3928 (67.8)	2543 (70.2)
N1	224 (3.9)	104 (2.9)
N2	420 (7.3)	211 (5.8)
NX	1203 (20.8)	756 (20.9)
Missing	17 (0.3)	10 (0.3)
M stage
M0	3696 (63.8)	2362 (65.2)
M1	1151 (19.9)	635 (17.5)
MX	931 (16.1)	622 (17.2)
Missing	14 (0.2)	5 (0.1)
Charlson Comorbidity Index^a (points)
No comorbidity (0)	3201 (55.3)	2085 (57.5)
Mild comorbidity (1)	1293 (22.3)	791 (21.8)
Intermediate comorbidity (2)	398 (6.9)	226 (6.2)
Severe comorbidity (3)	356 (6.1)	197 (5.4)
Missing	544 (9.4)	325 (9.0)

^aThe Charlson Comorbidity Index was calculated from 10 years before date of Renal Cell Carcinoma (RCC) diagnosis to 30 days before date of RCC diagnosis.